Statistik Asas
| CIK | 1819253 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to biote Corp.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp. |
|
| August 6, 2025 |
Biote Reports Second Quarter 2025 Financial Results Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase new clinic and procedure growth Decisive actions position Biote for sustainable long-term growth and value creation Second Quarter 2025 Financial Highlights • Revenue of $48. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2025 biote Corp. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40128 85-1791125 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 5, 2025 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 9, 2025 |
Biote Names Rich Barrera to Board of Directors Exhibit 99.1 Biote Names Rich Barrera to Board of Directors IRVING, TX – June 9, 2025 - biote Corp.(NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has elected Rich Barrera to the Board, effective immediately. “We are pleased to welcome Rich Barrera |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 2, 2025 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2025 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 9, 2025 |
Non-Employee Director Compensation Policy. Exhibit 10.1 biote Corp. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of biote Corp. (the “Company”) who is a non-employee director of the Company or any of its subsidiaries (each, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for Board service upon and following Jan |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp. |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 01, 2025 biote Corp. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40128 85-1791125 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| May 7, 2025 |
Biote Reports First Quarter 2025 Financial Results Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains 2025 financial outlook First Quarter 2025 Financial Highlights • Revenue of $49. |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2025 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 9, 2025 |
As filed with the Securities and Exchange Commission on April 9, 2025 Registration No. |
|
| April 9, 2025 |
Power of Attorney (included on the signature page to this registration statement). Table of Contents As filed with the Securities and Exchange Commission on April 9, 2025. |
|
| April 9, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 BIOTE CORP. |
|
| April 3, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 3, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| March 17, 2025 |
Exhibit 99.1 Transforming Healthy Aging 2 Transforming Healthy Aging Forward-Looking Statements Forward-Looking Statements Certain statements in this Presentation may be considered “forward-looking statements” within the meaning of the provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events of BioTE Holdings, LL |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2025 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 14, 2025 |
Description of the Registrant’s Securities. Exhibit 4.1 DESCRIPTION OF SECURITIES The following summary of the material terms of our securities is not intended to be a complete description of all of the rights and preferences of such securities. Because it is only a summary, it does not contain all of the information that may be important to you and is qualified by reference to our second amended and restated certificate of incorporation (t |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K 8 25.6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Cor |
|
| March 14, 2025 |
Exhibit 10.9 [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is (i) not material and (ii) the type of information that the registrant customarily and actually treats as private or confidential. CONSULTING AGREEMENT Execution Date: January 30, 2025 This Consulting Agreement (the “Agreement”) is executed as of the Execution Date forth above by a |
|
| March 14, 2025 |
Exhibit 10.8 January 30, 2025 Via Email Teresa S. Weber [email protected] Re: Transition and Retirement Agreement Dear Terry: This letter sets forth the substance of the transition and separation agreement (the “Agreement”) that BioTE Medical, LLC (the “Company”) is offering to you to aid in your transition. 1. Transition and Separation. By executing this Agreement, you agree that your service |
|
| March 14, 2025 |
Exhibit 10.11 January 29, 2025 Mr. Bret Christensen (via e-mail) Re: Offer of Employment Dear Bret: I am pleased to offer you an initial position with BioTE Medical, LLC (the “Company”), as its Chief Executive Officer (“CEO”) working from the Company’s Dallas, Texas, office. Of course, the Company may change your position, duties, and work location from time to time in its discretion. For purposes |
|
| March 14, 2025 |
Exhibit 19.1 BIOTE CORP. INSIDER TRADING POLICY Introduction During the course of your relationship with biote Corp. (the “Company”), you may receive important material information that is not yet publicly available (“inside information” or “material nonpublic information”) about the Company or about other publicly traded companies with which the Company has business relationships with. Material n |
|
| March 14, 2025 |
Non-Employee Director Compensation Policy Exhibit 10.1 biote Corp. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of biote Corp. (the “Company”) who is a non-employee director of the Company or any of its subsidiaries (each, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for Board service upon and following Jan |
|
| March 12, 2025 |
Exhibit 99.1 Biote Reports Fourth Quarter and Full Year 2024 Financial Results Strengthened business with launch of BioteRx and enhancements to Biote Method Provides fiscal 2025 outlook IRVING, TX – March 12, 2025 - Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financi |
|
| March 12, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2025 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| January 30, 2025 |
Exhibit 99.1 Biote Announces CEO Retirement and Succession Plan Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company’s Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director IRVING, TX – January 30, 2025 – biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care th |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2025 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 13, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 22 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 58,565,824 Shares of Class A Common Stock Up to 62,289,796 Shares of Class A Common Stock This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 33 |
|
| November 13, 2024 |
biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 19 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pr |
|
| November 12, 2024 |
Exhibit 10.2 LEASE AGREEMENT ES 432-434 INDUSTRIAL, LLC Landlord AND F.H. INVESTMENTS, INC. d/b/a ASTERIA HEALTH Tenant AT 432 Industrial Lane Birmingham, AL 35211 i LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made by and between ES 432-434 INDUSTRIAL, LLC, a Delaware limited liability company (“Landlord”), and F.H. INVESTMENTS, INC., an Alabama corporation, d/b/a ASTERIA HEALTH (“Tenan |
|
| November 12, 2024 |
BTMD / biote Corp. / Bandera Partners LLC - AMENDMENT NO. 2 TO THE SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga208706btmd11122024.htm AMENDMENT NO. 2 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 biote Corp. (Name of Issuer) Class A common stock, par value $ |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp. |
|
| November 12, 2024 |
Exhibit 99.1 Biote Reports Third Quarter 2024 Financial Results Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages IRVING, TX – November 12, 2024 – Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormo |
|
| November 12, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 9, 2024 |
424B3 1 resales-1prosuppno2.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 21 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 58,565,824 Shares of Class A Common Stock Up to 62,289,796 Shares of Class A Common Stock This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our regi |
|
| August 9, 2024 |
Exhibit 10.6 Execution Version SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT (this “Agreement”), dated as of June 26, 2024 (the “Second Amendment Effective Date”), is entered into by and among BIOTE MEDICAL, LLC, a Texas limited liability company (the “Borrower”), BIOTE HOLDINGS, LLC, a Delaware limited liability company (“Holdings”), the other Guarantors party her |
|
| August 9, 2024 |
Separation Agreement, by and between BioTE Medical, LLC and Mary Puncochar, dated July 3, 2024. Exhibit 10.3 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS This is a Confidential Separation Agreement and General Release of Claims (“Agreement”) by and between Mary Puncochar (“Employee”) and BioTE Medical, LLC, a Texas limited liability company (together with its affiliates, parents, and subsidiaries the “Company”). Employee and Company collectively are referred to herein as t |
|
| August 9, 2024 |
Exhibit 10.5 Execution Version FIRST AMENDMENT TO CREDIT AGREEMENT AND WAIVER This FIRST AMENDMENT TO CREDIT AGREEMENT AND WAIVER (this “Agreement”), dated as of April 26, 2024 (the “First Amendment Effective Date”), is entered into by and among BIOTE MEDICAL, LLC, a Texas limited liability company (the “Borrower”), BIOTE HOLDINGS, LLC, a Delaware limited liability company (“Holdings”), the other |
|
| August 9, 2024 |
Settlement Agreement between the Company and Marci M. Donovitz, dated June 28, 2024. Exhibit 10.2 [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is (i) not material and (ii) the type of information that the registrant customarily and actually treats as private or confidential. SETTLEMENT AGREEMENT This Settlement Agreement (“Agreement”) is made by and among biote Corp. (“Biote”), BioTE Medical, LLC (“Medical”), BioTE Holdings |
|
| August 9, 2024 |
biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 18 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pr |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp. |
|
| August 8, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 8, 2024 |
Exhibit 99.1 Biote Reports Second Quarter 2024 Financial Results Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance IRVING, TX – August 8, 2024 - Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic w |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 28, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 21, 2024 |
EX-99.1 Exhibit 99.1 Biote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout Shares IRVING, TX – June 20, 2024 – biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a b |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 21, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 10, 2024 |
biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 17 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pr |
|
| May 10, 2024 |
[*****] Text omitted for confidential treatment. The redacted information has been excluded because it is (i) not material and (ii) the type of information that the registrant customarily and actually treats as private or confidential. EXHIBIT 10.1 SETTLEMENT AGREEMENT This Settlement Agreement (“Agreement”) is made by and among biote Corp. (“Biote”), BioTE Medical, LLC (“Medical”), BioTE Holdings |
|
| May 10, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 20 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 58,565,824 Shares of Class A Common Stock Up to 62,289,796 Shares of Class A Common Stock This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 33 |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp. |
|
| May 10, 2024 |
Settlement Agreement between the Company and Dr. Gary S. Donovitz, dated April 23, 2024. [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is (i) not material and (ii) the type of information that the registrant customarily and actually treats as private or confidential. EXHIBIT 10.1 SETTLEMENT AGREEMENT This Settlement Agreement (“Agreement”) is made by and among biote Corp. (“Biote”), BioTE Medical, LLC (“Medical”), BioTE Holdings |
|
| May 10, 2024 |
Settlement Agreement between the Company and Dr. Gary S. Donovitz, dated April 23, 2024. [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is (i) not material and (ii) the type of information that the registrant customarily and actually treats as private or confidential. EXHIBIT 10.1 SETTLEMENT AGREEMENT This Settlement Agreement (“Agreement”) is made by and among biote Corp. (“Biote”), BioTE Medical, LLC (“Medical”), BioTE Holdings |
|
| May 7, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 7, 2024 |
Exhibit 99.1 Biote Reports First Quarter 2024 Financial Results Procedure revenue growth and strengthened profitability drive solid financial performance Phased launch of BioteRx remains on track Reaffirms 2024 financial guidance, with an acceleration in second half growth IRVING, TX – May 7, 2024—Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 23, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 29, 2024 |
Exhibit 99.1 Biote Announces Definitive Settlement with Founder Company to repurchase all of Founder’s 18.4 million shares at $4.17 per share IRVING, TX – April 29, 2024 – biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has entered int |
|
| April 11, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 9, 2024 |
biote Corp. Up to 5,000,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus relates to the resale of up to 5,000,000 shares (the “Shares”) of our Class A common stock, $0.0001 par value per share (the “Class A common stock”), by YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Selling Securityholder”) |
|
| April 9, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS biote Corp. Up to 58,565,824 Shares of Class A Common Stock and Up to 62,289,796 Shares of Class A Common Stock Offered by the Selling Securityholders This prospectus relates to the issuance by us of an aggregate of up to 58,565,824 shares of Class A Common Stock issuable to the Members (as defined below) upo |
|
| April 3, 2024 |
As filed with the Securities and Exchange Commission on April 3, 2024 As filed with the Securities and Exchange Commission on April 3, 2024 Registration No. |
|
| April 3, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 BIOTE CORP. |
|
| April 1, 2024 |
Employment Agreement, effective May 30, 2023, by and between BioTE Medical, LLC and Mary Puncochar. EX-10.22 Exhibit 10.22 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Mary Puncochar (“Executive”) and BioTE Medical, LLC (the “Company”), and effective as of May 30, 2023 (“Effective Date”). WHEREAS, Executive is employed by the Company as its Chief Commercial Officer (“CCO”); WHEREAS, the Company desires to continue to employ Executive and, in con |
|
| April 1, 2024 |
Exhibit 10.1 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of biote Corp. (the “Company”) who is a non-employee director of the Company or any of its subsidiaries (each, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for Board service upon and following January 1, 2024 |
|
| April 1, 2024 |
Table of Contents As filed with the Securities and Exchange Commission March 29, 2024. |
|
| April 1, 2024 |
Employment Agreement, effective May 30, 2023, by and between BioTE Medical, LLC and Mary Puncochar. EX-10.22 Exhibit 10.22 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Mary Puncochar (“Executive”) and BioTE Medical, LLC (the “Company”), and effective as of May 30, 2023 (“Effective Date”). WHEREAS, Executive is employed by the Company as its Chief Commercial Officer (“CCO”); WHEREAS, the Company desires to continue to employ Executive and, in con |
|
| April 1, 2024 |
Non-Employee Director Compensation Policy. EX-10.1 Exhibit 10.1 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of biote Corp. (the “Company”) who is a non-employee director of the Company or any of its subsidiaries (each, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for Board service upon and following January |
|
| April 1, 2024 |
EX-10.23 Exhibit 10.23 March 3, 2024 Mary Puncochar Re: Change in Employment Status Dear Mary: As discussed, you and Biote® Medical, LLC (the “Company”) have mutually agreed to change your status from a full-time employee to a part-time employee and adjusting your role and responsibilities, accordingly. This letter agreement (the “Agreement”) sets forth the terms of your modified role, compensatio |
|
| April 1, 2024 |
Power of Attorney (Included on signature page hereto). Table of Contents As filed with the Securities and Exchange Commission March 29, 2024. |
|
| April 1, 2024 |
EX-10.23 Exhibit 10.23 March 3, 2024 Mary Puncochar Re: Change in Employment Status Dear Mary: As discussed, you and Biote® Medical, LLC (the “Company”) have mutually agreed to change your status from a full-time employee to a part-time employee and adjusting your role and responsibilities, accordingly. This letter agreement (the “Agreement”) sets forth the terms of your modified role, compensatio |
|
| March 15, 2024 |
biote Corp. Incentive Compensation Recoupment Policy. Exhibit 97.1 biote Corp. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of biote Corp., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing |
|
| March 15, 2024 |
Exhibit 10.21 January 8, 2024 Samar Kamdar 7042 Coronado Avenue Dallas, TX 75214 Re: Transition Agreement Dear Samar: This letter sets forth the substance of the Transition Agreement (the “Agreement”) which BioTE Medical, LLC (the “Company”) is offering to you to aid in your employment transition. 1. Transition Period. As discussed, if you execute and return this Agreement by January 29, 2024 then |
|
| March 15, 2024 |
Exhibit 10.20 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Robert Peterson (“Executive”) and BioTE Medical, LLC (the “Company”), and effective as of January 8, 2024 (“Effective Date”). WHEREAS, Executive shall be employed by the Company as its Chief Financial Officer (“CFO”); WHEREAS, the Company desires to employ Executive and, in connection ther |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K 8 25.6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Cor |
|
| March 15, 2024 |
Description of the Registrant’s Securities. Exhibit 4.1 DESCRIPTION OF SECURITIES The following summary of the material terms of our securities is not intended to be a complete description of all of the rights and preferences of such securities. Because it is only a summary, it does not contain all of the information that may be important to you and is qualified by reference to our second amended and restated certificate of incorporation (t |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 14, 2024 |
Exhibit 99.1 Transforming Healthy Aging 2 Transforming Healthy Aging Forward-Looking Statements Forward-Looking Statements Certain statements in this Presentation may be considered “forward-looking statements” within the meaning of the provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events of BioTE Holdings, LL |
|
| March 12, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 12, 2024 |
Exhibit 99.1 Biote Reports Fourth Quarter and Full Year 2023 Financial Results Grew practitioner network to over 7,100 from 6,400 in 2022 Launched BioteRx, our new hormone and therapeutic wellness offerings Enhancing shareholder value with agreement to repurchase 18.4M founders’ shares in addition to a separate $20M share repurchase program Reaffirms 2024 financial guidance, with an acceleration i |
|
| February 21, 2024 |
424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 19 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registratio |
|
| February 21, 2024 |
biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 16 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). T |
|
| February 20, 2024 |
Exhibit 99.1 Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder’s Shares Company to repurchase approximately 18.4 million Class A shares and Paired Interests at $4.17 per share IRVING, TX – February 20, 2024 – biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimiza |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| February 14, 2024 |
US0906831039 / BIOTE CORP 0.00000000 / Roystone Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
US0906831039 / BIOTE CORP 0.00000000 / Roystone Capital Management LP Passive Investment SC 13G/A 1 d10973642a13g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* biote Corp. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 090683103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| February 13, 2024 |
SC 13G/A 1 btmda121324.htm ROBECO INVESTMENT MANAGEMENT INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biote Corp (Name of Issuer) Common Stock (Title of Class of Securities) 090683103 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate |
|
| February 13, 2024 |
SC 13G/A 1 sc13ga108706btmd02142024.htm AMENDMENT NO. 1 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 biote Corp. (Name of Issuer) Class A common stock, par value $ |
|
| February 12, 2024 |
US0906831039 / BIOTE CORP 0.00000000 / LMR Partners LLP Passive Investment SC 13G/A 1 formsc13ga-biote.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* biote Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 090683103 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the app |
|
| January 25, 2024 |
Biote Announces $20 Million Share Repurchase Authorization Exhibit 99.1 Biote Announces $20 Million Share Repurchase Authorization IRVING, TX – January 25, 2024 – biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has approved a $20 million share repurchase program of the |
|
| January 25, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 25, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 17, 2024 |
biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 15 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pr |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 17, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 17, 2024 |
Biote Provides Preliminary 2023 Results and Initial 2024 Guidance Exhibit 99.1 Biote Provides Preliminary 2023 Results and Initial 2024 Guidance IRVING, TX – January 17, 2024 – biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that management expects 2023 revenue and Adjusted EBITDA to be slightly below p |
|
| January 17, 2024 |
Exhibit 99.2 Biote to Purchase Asteria Health Strategic and accretive transaction enables vertical integration of hormone product manufacturing IRVING, TX – January 17, 2024 – biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive a |
|
| January 17, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 18 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration stat |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number |
|
| January 11, 2024 |
Biote Names Robert Peterson as Chief Financial Officer Exhibit 99.1 Biote Names Robert Peterson as Chief Financial Officer IRVING, TX — January 11, 2024 — biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr |
|
| November 14, 2023 |
biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 14 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pr |
|
| November 14, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 17 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration stat |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp. |
|
| November 7, 2023 |
Exhibit 99.1 Biote Reports Third Quarter 2023 Financial Results Achieves Progress in Test of Complementary Wellness Therapeutics Reiterates 2023 Financial Guidance IRVING, TX – November 7, 2023 – Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the third quarter ended September 3 |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 5, 2023 |
1875 W. Walnut Hill Ln, #100 Irving, TX 75038 October 5, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Eric Atallah Tara Harkins RE: Biote Corp. Form 10-K for the Year Ended December 31, 2022 Filed March 29, 2023 Form 8-K Filed August 10, 2023 File No. 001-40128 Ladies and G |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp. |
|
| August 11, 2023 |
biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 13 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pr |
|
| August 11, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 16 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration stat |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 10, 2023 |
EX-99.1 Exhibit 99.1 Biote Reports Second Quarter 2023 Financial Results Solid Second Quarter Revenue Growth Continued Progress to Optimize Capital Structure and Enhance Share Liquidity Expansive Strategic Approach Targeting Therapeutic Wellness and Men’s Health Categories IRVING, TX – August 10, 2023 - Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delive |
|
| June 23, 2023 |
US0906831039 / BIOTE CORP 0.00000000 / Roystone Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 15, 2023 |
US0906831039 / BIOTE CORP 0.00000000 / 325 CAPITAL LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 biote Corp. (Name of Issuer) Common Stock, $0.0001 par value Common Stock, Par Value $0.001 per share (Title of Class of Securities) 090683103 (CUSIP Number) Michael Braner 325 Capital LLC 757 Third Avenue, 20th Floor New York, NY 10017 646-774-2904 (Name, Address and Tele |
|
| June 15, 2023 |
EXHIBIT 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Stock, par value $0.0001 per share, of biote Corp., a Delaware corporation. This Joint Filin |
|
| June 13, 2023 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated June 13, 2023 with respect to the Class A common stock, par value $0.0001 per share, of biote Corp., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) |
|
| June 13, 2023 |
US0906831039 / BIOTE CORP 0.00000000 / Bandera Partners LLC - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 biote Corp. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 090683103 (CUSIP Number) June |
|
| June 9, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 8, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 9, 2023 |
biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 12 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). T |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 8, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 9, 2023 |
424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 15 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registratio |
|
| June 9, 2023 |
EX-10.1 Exhibit 10.1 AMENDMENT NO. 1 TO WARRANT AGREEMENT This Amendment (this “Amendment”) is made as of June 8, 2023 by and between biote Corp., a Delaware corporation (the “Company”) (f/k/a Haymaker Acquisition Corp. III), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”), and constitutes an amendment to that certain Warrant Agreement |
|
| June 9, 2023 |
SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) biote Corp. (Name of Subject Company and Filing Person (Issuer)) Warrants to Acquire Shares of Class A Common Stock (Title of Class of Securities) 090683111 (CUSIP Number of Class of Securiti |
|
| June 9, 2023 |
EX-99.1 Exhibit 99.1 Biote Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants IRVING, TX – June 8, 2023 - Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive healthcare through the delivery of personalized hormone therapy, today announced the expiration and results of its previously announced (i) offer to each |
|
| June 7, 2023 |
biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 11 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). T |
|
| June 7, 2023 |
biote Corp. 5,217,392 Shares of Class A Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS biote Corp. 5,217,392 Shares of Class A Common Stock This is a public offering of shares of our Class A common stock, par value $0.0001 per share (the “Class A common stock”). The selling stockholder identified in this prospectus is offering 5,217,392 shares of Class A common stock. The selling stockhol |
|
| June 7, 2023 |
U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 5, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 7, 2023 |
424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 14 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registratio |
|
| June 6, 2023 |
BIOTE CORP. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 June 6, 2023 VIA EDGAR CORRESP BIOTE CORP. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 June 6, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Christina Chalk and Blake Grady RE: biote Corp. Registration Statement on Form S-4 (File No. 333-271782) Acceleration Request Requested Date: June 7, 2023 Requested Time: 5:00 P.M. Ea |
|
| May 23, 2023 |
CORRESP Ryan Sansom +1 617 937 2335 [email protected] May 23, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance Office Mergers & Acquisitions 100 F Street, N.E. Washington, DC 20549 Attn: Christina Chalk and Blake Grady Re: biote Corp. Schedule TO-I filed May 9, 2023 File No. 005-92341 Form S-4 filed May 9, 2023 Form S-4/A filed May 16, 2023 File No. 333-271782 Dear Ms. |
|
| May 23, 2023 |
Table of Contents As filed with the Securities and Exchange Commission on May 23 , 2023 Registration No. |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 16, 2023 |
Form of Letter to Clients of Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. EX-99.4 Exhibit 99.4 LETTER TO CLIENTS OF BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer To Exchange Warrants to Acquire Shares of Class A Common Stock of biote Corp. for Shares of Class A Common Stock of biote Corp. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN |
|
| May 16, 2023 |
424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 13 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part |
|
| May 16, 2023 |
Table of Contents As filed with the Securities and Exchange Commission on May 1 6 , 2023 Registration No. |
|
| May 16, 2023 |
Form of Tender and Support Agreement, by and between the Company and Supporting Stockholders. EX-10.23 Exhibit 10.23 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of [●], 2023, is entered into by and among biote Corp., a Delaware corporation (the “Company”), each of the persons listed on Schedule A hereto (each, a “Public Warrant Holder”) and each of the persons listed on Schedule B hereto (each, a “Private Warrant Holder” and, together with th |
|
| May 16, 2023 |
biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 10 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration |
|
| May 16, 2023 |
Form of Letter of Transmittal and Consent. EX-99.1 Exhibit 99.1 LETTER OF TRANSMITTAL AND CONSENT Offer To Exchange Warrants to Acquire Shares of Class A Common Stock of biote Corp. for Shares of Class A Common Stock of biote Corp. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN STANDARD TIME, ON JUNE 7, 2023, OR SUCH LATER TIME AND DAT |
|
| May 16, 2023 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. EX-99.3 Exhibit 99.3 LETTER TO BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer To Exchange Warrants to Acquire Shares of Class A Common Stock of biote Corp. for Shares of Class A Common Stock of biote Corp. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN STANDARD TI |
|
| May 15, 2023 |
DEL AM May 12, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: biote Corp. Registration Statement on Form S-4 (File No. 333-271782) Ladies and Gentlemen: Reference is made to the Registration Statement on Form S-4 (File No. 333-271782) filed by biote Corp. on May 9, 2023 (the “Registration Statement”). Pursuant to |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp. |
|
| May 10, 2023 |
biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 9 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). Th |
|
| May 10, 2023 |
424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 12 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registratio |
|
| May 10, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 9, 2023 |
Form of Tender and Support Agreement, by and between the Company and Supporting Stockholders. EX-10.23 Exhibit 10.23 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of [●], 2023, is entered into by and among biote Corp., a Delaware corporation (the “Company”), each of the persons listed on Schedule A hereto (each, a “Public Warrant Holder”) and each of the persons listed on Schedule B hereto (each, a “Private Warrant Holder” and, together with th |
|
| May 9, 2023 |
EX-99.1 Exhibit 99.1 Biote Reports First Quarter 2023 Financial Results New Initiative Targets Long-term Growth Opportunity in Men’s Health Company Launches Warrant Exchange Offer and Consent Solicitation Maintains 2023 Financial Guidance IRVING, TX – May 9, 2023—Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today |
|
| May 9, 2023 |
Youâve Exceeded the SECâs Traffic Limit EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table SC TO-I (Form Type) BIOTE CORP. |
|
| May 9, 2023 |
Form of Letter of Transmittal and Consent. EX-99.1 Exhibit 99.1 LETTER OF TRANSMITTAL AND CONSENT Offer To Exchange Warrants to Acquire Shares of Class A Common Stock of biote Corp. for Shares of Class A Common Stock of biote Corp. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN STANDARD TIME, ON JUNE 7, 2023, OR SUCH LATER TIME AND DAT |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 biote Corp. (Name of Subject Company and Filing Person (Issuer)) Warrants to Acquire Shares of Class A Common Stock (Title of Class of Securities) 090683111 (CUSIP Number of Class of Securities) Teresa S. Weber Chief Ex |
|
| May 9, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-4 (Form Type) BIOTE CORP. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Fo |
|
| May 9, 2023 |
Power of Attorney (Included on signature page hereto). Table of Contents As filed with the Securities and Exchange Commission on May 9, 2023 Registration No. |
|
| May 9, 2023 |
Form of Letter to Clients of Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. EX-99.4 Exhibit 99.4 LETTER TO CLIENTS OF BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer To Exchange Warrants to Acquire Shares of Class A Common Stock of biote Corp. for Shares of Class A Common Stock of biote Corp. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 9, 2023 |
Biote Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants EX-99.2 Exhibit 99.2 Biote Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants IRVING, TX – May 9, 2023 - Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (th |
|
| May 9, 2023 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. EX-99.3 Exhibit 99.3 LETTER TO BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer To Exchange Warrants to Acquire Shares of Class A Common Stock of biote Corp. for Shares of Class A Common Stock of biote Corp. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN STANDARD TI |
|
| May 9, 2023 |
Form of Notice of Guaranteed Delivery. EX-99.2 Exhibit 99.2 NOTICE OF GUARANTEED DELIVERY OF WARRANTS OF BIOTE CORP. Pursuant to the Prospectus/Offer to Exchange dated May 9, 2023 Instructions for Use Unless defined herein, terms used in this Notice of Guaranteed Delivery shall have definitions set forth in the Prospectus/Offer to Exchange dated May 9, 2023. This Notice of Guaranteed Delivery, or one substantially in the form hereof, m |
|
| April 24, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 BIOTE CORP. |
|
| April 24, 2023 |
Power of Attorney (contained on the signature page hereto). S-8 As filed with the Securities and Exchange Commission on April 24, 2023 Registration No. |
|
| April 14, 2023 |
DEF 14A 1 d381833ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| April 13, 2023 |
biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus relates to the resale of up to 5,000,000 shares (the “Shares”) of our Class A common stock, $0.0001 par value per share (the “Class A common stock”), by YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Selling Securityho |
|
| April 13, 2023 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS biote Corp. Up to 72,069,990 Shares of Class A Common Stock and Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants Offered by the Selling Securityholders This prospectus relates to the issuance by us of an aggregate of up to 72,069,990 shares of our Class A Common Stock, $0.0001 pa |
|
| April 6, 2023 |
As filed with the Securities and Exchange Commission April 5 , 2023. Registration No. 333-265714 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 biote Corp. (Exact name of Registrant as specified in its charter) Delaware 2833 85-1791125 (State or other jurisdiction of incorpor |
|
| April 6, 2023 |
As filed with the Securities and Exchange Commission April 5, 2023. Registration No. 333-266433 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST- EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 biote Corp. (Exact name of Registrant as specified in its charter) Delaware 2833 85-1791125 (State or other jurisdiction of incorpor |
|
| March 30, 2023 |
biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 7 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pro |
|
| March 30, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 11 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration stat |
|
| March 30, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 10 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration stat |
|
| March 30, 2023 |
biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 8 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pro |
|
| March 29, 2023 |
EX-10 3 btmd-ex101.htm EX-10.1 Exhibit 10.1 biote Corp. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of biote Corp. (the “Company”) who is a non-employee director of the Company or any of its subsidiaries (each, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for Board |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (AMENDMENT NO. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (AMENDMENT NO. |
|
| March 29, 2023 |
Description of the Registrant’s Securities. Exhibit 4.3 DESCRIPTION OF SECURITIES The following summary of the material terms of our securities is not intended to be a complete description of all of the rights and preferences of such securities. Because it is only a summary, it does not contain all of the information that may be important to you, and is qualified by reference to our Charter, the Bylaws, the A&R IRA and the Warrant Agreement |
|
| March 29, 2023 |
Exhibit 10.17 biote Corp. 2022 Equity Incentive Plan Adopted by the Board of Directors: May 26, 2022 Approved by the Stockholders: May 24, 2022 1. General. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affilia |
|
| March 29, 2023 |
25.6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp. |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (AMENDMENT NO. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (AMENDMENT NO. |
|
| March 28, 2023 |
EX-99.1 Exhibit 99.1 Biote Reports Fourth Quarter and Full Year 2022 Financial Results Achieved Full Year 2022 Record Revenue and Adjusted EBITDA for Full Year 2022 Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of $56-60 million Significantly Increased Trading Liquidity with Recent Successful Secondary Offering IRVING, TX – March 28, 2023—Biote (NASDAQ: BTMD), a leading solutions pro |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 24, 2023 |
biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 6 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). Th |
|
| March 24, 2023 |
424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 9 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 24, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| February 22, 2023 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF biote CORP. (THE “CORPORATION”) February 21, 2023 ARTICLE I. OFFICES Section 1.1. Registered Office. The registered office of the Corporation within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware or (b) the office of the corporation or individual acting as the Corpora |
|
| February 17, 2023 |
US0906831039 / BIOTE CORP 0.00000000 / Roystone Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
US0906831039 / BIOTE CORP 0.00000000 / LMR Partners LLP - SC 13G/A Passive Investment SC 13G/A 1 d432263dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* biote Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 090683103 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check |
|
| February 14, 2023 |
US0906831039 / BIOTE CORP 0.00000000 / GLAZER CAPITAL, LLC Passive Investment SC 13G/A 1 btmd20221231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 biote Corporation (Name of Issuer) Class A common stock, $0.0001 par value per share (Title of Class of Securities) 090683103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 14, 2023 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 d432263dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint fil |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Biote Corp (Name of Issuer) Common Stock (Title of Class of Securities) 090683103 (CUSIP Number) January 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d- |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* biote Corp.** (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 090683103 (CUSIP Number) 31 December 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| January 6, 2023 |
biote Corp. 7,391,305 Shares of Common Stock 424B4 1 d344838d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-268748 PROSPECTUS biote Corp. 7,391,305 Shares of Common Stock This is a public offering of shares of our Class A common stock, par value $0.0001 per share (the “Class A common stock”). The selling stockholders identified in this prospectus are offering 7,391,305 shares of Class A common stock. |
|
| January 3, 2023 |
Form of Underwriting Agreement. Exhibit 1.1 7,391,305 biote Corp. Class A Common Stock UNDERWRITING AGREEMENT January [?], 2023 TRUIST SECURITIES, INC. 3333 Peachtree Road, NE, 11th Floor Atlanta, Georgia 30326 COWEN AND COMPANY, LLC 599 Lexington Ave., 25th floor New York, NY 10022 ROTH CAPITAL PARTNERS, LLC 888 San Clemente Dr. Newport Beach, CA 92660 As Representatives of the several Underwriters named in Schedule I attached |
|
| January 3, 2023 |
As filed with the Securities and Exchange Commission January 3, 2023 Table of Contents As filed with the Securities and Exchange Commission January 3, 2023 Registration No. |
|
| January 3, 2023 |
BIOTE CORP. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 January 3, 2023 VIA EDGAR CORRESP 1 filename1.htm BIOTE CORP. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 January 3, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara RE: biote Corp. Registration Statement on Form S-1 (File No. 333-268748) Acceleration Request Requested Date: January 3, 2023 Requested Time: 4:30 P. |
|
| January 3, 2023 |
* * * [Signature Page Follows] January 3, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 12, 2022 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) biote Corp. |
|
| December 12, 2022 |
Power of Attorney (included on signature page hereto). Table of Contents As filed with the Securities and Exchange Commission December 9, 2022 Registration No. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp. |
|
| November 14, 2022 |
424B3 1 bioteresales-1prosup.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 8 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which |
|
| November 14, 2022 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 8 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the ?Prospectus?), which forms a part of our registration state |
|
| November 14, 2022 |
Exhibit 10.3 August 26, 2022 (as modified on August 31, 2022) Robbin Gibbins Re: Transition Agreement Dear Robb: This letter sets forth the substance of the Transition Agreement (the ?Agreement?) which BioTE Medical, LLC (the ?Company?) is offering to you to aid in your employment transition. 1. Transition Period. As discussed, if you execute and return this Agreement by September 7, 2022 then you |
|
| November 14, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into by and between Samar Kamdar (?Executive?) and BioTE Medical, LLC (the ?Company?), and effective as of July 25, 2022 (?Effective Date?). WHEREAS, Executive is employed by the Company as its Chief Financial Officer (?CFO?); WHEREAS, the Company desires to continue to employ Executive and, in connection ther |
|
| November 14, 2022 |
Exhibit 10.2 Amendment to Employment Agreement This Amendment to Employment Agreement (the ?Amendment?) is entered into this 24th day of August 2022 (the ?Effective Date?), by and between Samar Kamdar (the ?Executive?) and BioTE Medical, LLC (the ?Company?). Recitals A. The Company and Executive have entered into that certain Employment Agreement dated as of July 25, 2022 (the ?Employment Agreemen |
|
| November 14, 2022 |
biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 1 bioteelocs-1prosupp.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 5 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended ( |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 8, 2022 |
Exhibit 99.1 Biote Reports Third Quarter Financial Results Strong Third Quarter Revenue of $42 million Driven by Growth in Procedures 2022 Revenue and Adjusted EBITDA Expected at Upper End of Guidance IRVING, TX ? November 8, 2022 - Biote (NASDAQ: BTMD), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced financial results for the thir |
|
| November 7, 2022 |
biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 4 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pro |
|
| November 7, 2022 |
424B3 1 d387411d424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 7 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms |
|
| November 7, 2022 |
Biote Appoints Debby Morris to Board of Directors Exhibit 99.1 Biote Appoints Debby Morris to Board of Directors IRVING, TX ? November 7, 2022 ? biote Corp. (Nasdaq: BTMD) (?Biote? or the ?Company?), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote?s Board of Directors. Ms. Morris brings more than three decades of experience in directing fi |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 12, 2022 |
US0906831039 / BIOTE CORP 0.00000000 / LMR Partners LLP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* biote Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 090683103 (CUSIP Number) October 6, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 10, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 11, 2022 |
Biote Releases Updated Corporate Presentation for October 2022 Exhibit 99.1 Biote Releases Updated Corporate Presentation for October 2022 October 10, 2022 IRVING, Texas?(BUSINESS WIRE)?Oct. 10, 2022?biote Corp. (Nasdaq: BTMD) (?Biote? or the ?Company?), a high growth, differentiated medical practice-building business within the hormone optimization space, today released a new Corporate Presentation, which the Company may use from time to time in communicatio |
|
| August 25, 2022 |
biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 3 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pro |
|
| August 25, 2022 |
EX-99.1 Exhibit 99.1 Biote Announces Approval to Relist on The Nasdaq Stock Market Company will resume trading under its existing symbols “BTMD” and “BTMDW” IRVING, TX, August 25, 2022 — biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has appro |
|
| August 25, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 25, 2022 |
8-A12B 1 d180209d8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 biote Corp. (Exact name of registrant as specified in its charter) Delaware 85-1791125 (State of incorporation or organization) (I.R.S. Employer Identification No.) |
|
| August 25, 2022 |
424B3 1 d399424d424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 6 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms |
|
| August 24, 2022 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 5 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the ?Prospectus?), which forms a part of our registration state |
|
| August 24, 2022 |
biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 2 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pro |
|
| August 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 24, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 24, 2022 |
Biote Appoints Samar Kamdar as Chief Financial Officer Exhibit 99.1 Biote Appoints Samar Kamdar as Chief Financial Officer IRVING, TX, August 24, 2022 ? biote Corp. (?Biote? or the ?Company?), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has appointed Samar Kamdar as its Chief Financial Officer. Mr. Kamdar will oversee Biote?s financial operations with a focus on drivin |
|
| August 16, 2022 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 4 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the ?Prospectus?), which forms a part of our registration state |
|
| August 16, 2022 |
biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 1 bioteelocs-1prosupp.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 1 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended ( |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp. |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No.1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Comm |
|
| August 15, 2022 |
Biote Issues Correction to Second Quarter Operating Loss and Net Income Exhibit 99.1 Biote Issues Correction to Second Quarter Operating Loss and Net Income IRVING, TX, August 15, 2022 ?Biote today issued a correction to operating loss and net income for the three and six month periods ended June 30, 2022 in the press release titled ?Biote Reports Second Quarter 2022 Financial Results,? issued on August 9, 2022. The other financial results reported in the original pre |
|
| August 10, 2022 |
Exhibit 99.1 Biote Reports Second Quarter 2022 Financial Results Company generates accelerated Revenue, net income and adjusted EBITDA growth, and raises 2022 adjusted EBITDA guidance *Revised Dial-in Information for the Conference Call* IRVING, TX, August 9, 2022 ? Biote, a high growth, differentiated medical practice-building business within the hormone optimization space, today announced financ |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 20, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 9, 2022 |
biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 1 d385770d424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus relates to the resale of up to 5,000,000 shares (the “Shares”) of our Class A common stock, $0.0001 par value per share (the “Class A common stock”), by YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Selling Se |
|
| August 3, 2022 |
Exhibit 99.3 BIOTE CORP. STOCK OPTION GRANT NOTICE (2022 EQUITY INCENTIVE PLAN) biote Corp. (the ?Company?), pursuant to the Company?s 2022 Equity Incentive Plan (the ?Plan?), has granted to you (?You,? or ?Optionholder?) an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). Your Option is subject to all of the terms and conditions as set forth herein, in t |
|
| August 3, 2022 |
Exhibit 99.2 BIOTE CORP. 2022 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MAY 26, 2022 APPROVED BY THE STOCKHOLDERS: MAY 24, 2022 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series o |
|
| August 3, 2022 |
As filed with the Securities and Exchange Commission on August 3, 2022 As filed with the Securities and Exchange Commission on August 3, 2022 Registration No. |
|
| August 3, 2022 |
EX-FILING FEES 9 d380602dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 BIOTE CORP. Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(6) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2022 Equity Incentive Plan (Class A common stock, $0. |
|
| August 3, 2022 |
BIOTE CORP. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 August 3, 2022 VIA EDGAR CORRESP 1 filename1.htm BIOTE CORP. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 August 3, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Dorrie Yale RE: biote Corp. Registration Statement on Form S-1 File No. 333-266433 Acceleration Request Requested Date: August 5, 2022 Requested Time: 4:05 P.M. East |
|
| August 3, 2022 |
Exhibit 99.1 BIOTE CORP. 2022 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MAY 26, 2022 APPROVED BY THE STOCKHOLDERS: MAY 24, 2022 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliat |
|
| August 3, 2022 |
Exhibit 99.4 BIOTE CORP. RSU AWARD GRANT NOTICE (2022 EQUITY INCENTIVE PLAN) biote Corp. (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified, and on the terms set forth, below in consideration of Participant?s services (the ?RSU Award?). The RSU Award is subject to all of the terms and conditions as set forth herein and in the Company?s 2022 Equity |
|
| August 1, 2022 |
Table of Contents As filed with the Securities and Exchange Commission July 29, 2022. |
|
| August 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) biote Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to |
|
| July 28, 2022 |
Exhibit 10.1 Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential. STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this ?Agreement?) dated as of July 27, 2022 is made by and between YA II PN, LTD., a Cayman Islands exempt limited partnership |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 28, 2022 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 3 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the ?Prospectus?), which forms a part of our registration state |
|
| July 19, 2022 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 1 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the ?Prospectus?), which forms a part of our registration state |
|
| July 19, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS biote Corp. Up to 72,069,990 Shares of Class A Common Stock and Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants Offered by the Selling Securityholders This prospectus relates to the issuance by us of an aggregate of up to 72,069,990 shares of our Class A Common Stock, $0.0001 par valu |
|
| July 19, 2022 |
Exhibit 10.1 Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (as it may be amended, supplemented or restated from time to time in accordance with the terms of this |
|
| July 19, 2022 |
424B3 1 d378763d424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 2 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms |
|
| July 19, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 18, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 19, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 19, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 15, 2022 |
BIOTE CORP. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 July 15, 2022 VIA EDGAR BIOTE CORP. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 July 15, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford and Laura Crotty RE: biote Corp. Registration Statement on Form S-1 File No. 333-265714 Acceleration Request Requested Date: July 19, 2022 Requested Time: 4:05 P.M. Eastern T |
|
| July 11, 2022 |
Ryan Sansom +1 617 937 2335 [email protected] July 11, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attn: Daniel Crawford and Laura Crotty Re: biote Corp. Amendment No. 2 to Registration Statement on Form S-1 Filed June 28, 2022 File No. 333-265714 Dear Mr. Crawford and Ms. Crotty: On behalf of our cli |
|
| July 11, 2022 |
As filed with the Securities and Exchange Commission July 11, 2022. Table of Contents As filed with the Securities and Exchange Commission July 11, 2022. |
